Epigenetic inactivation of the candidate tumor suppressor gene ASC/TMS1 in human renal cell carcinoma and its role as a potential therapeutic target

Oncotarget

Volumn 6, Issue 26, 2015, Pages 22706-22723

  Liu, Qianling ^a   Jin, Jie ^a   Ying, Jianming ^b   Cui, Yun ^a   Sun, Mengkui ^a   Zhang, Lian ^a   Fan, Yu ^a   Xu, Ben ^a   Zhang, Qian ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

ASC TMS1; Chemosensitivity; DNA methylation; Renal cell carcinoma; Tumor suppressor

Indexed keywords

DECITABINE; DNA; PROTEIN ASC; PROTEIN P21; PROTEIN P53; PROTEIN TMS1; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CYTOSKELETON PROTEIN; PYCARD PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASC GENE; CANCER GRADING; CANCER INHIBITION; CELL CULTURE; CELL INVASION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE REPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; RENAL CANCER CELL LINE; TMS1 GENE; TUMOR SUPPRESSOR GENE; ANIMAL; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; KIDNEY TUMOR; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HETEROGRAFTS; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84941253821     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4256     Document Type: Article

References (46)

1. Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T, van Poppel H, Wood CG. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. EUR UROL. 2010; 58:819-828.
2. Okuda H, Toyota M, Ishida W, Furihata M, Tsuchiya M, Kamada M, Tokino T, Shuin T. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. ONCOGENE. 2006; 25:1733-1742.
3. Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, Teh B, Latif F, Maher ER. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. CANCER RES. 2005; 65:4598-4606.
4. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. CANCER RES. 2001; 61:7277-7281.
5. Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, Clarke N, Latif F, Maher ER. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. ONCOGENE. 2011; 30:1390-1401.
6. McConnell BB, Vertino PM. TMS1/ASC: the cancer connection. APOPTOSIS. 2004; 9:5-18.
7. Masumoto J, Taniguchi S, Ayukawa K, Sarvotham H, Kishino T, Niikawa N, Hidaka E, Katsuyama T, Higuchi T, Sagara J. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J BIOL CHEM. 1999; 274:33835-33838.
8. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylationinduced gene silencing in human breast cancers. CANCER RES. 2000; 60:6236-6242.
9. McConnell BB, Vertino PM. Activation of a caspase-9-mediated apoptotic pathway by subcellular redistribution of the novel caspase recruitment domain protein TMS1. CANCER RES. 2000; 60:6243-6247.
10. Masumoto J, Dowds TA, Schaner P, Chen FF, Ogura Y, Li M, Zhu L, Katsuyama T, Sagara J, Taniguchi S, Gumucio DL, Nunez G, Inohara N. ASC is an activating adaptor for NF-kappa B and caspase-8-dependent apoptosis. BIOCHEM BIOPHYS RES COMMUN. 2003; 303:69-73.
11. Hong S, Hwang I, Lee YS, Park S, Lee WK, Fernandes-Alnemri T, Alnemri ES, Kim YS, Yu JW. Restoration of ASC expression sensitizes colorectal cancer cells to genotoxic stress-induced caspase-independent cell death. CANCER LETT. 2013; 331:183-191.
12. Das PM, Ramachandran K, Vanwert J, Ferdinand L, Gopisetty G, Reis IM, Singal R. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. MOL CANCER. 2006; 5:28.
13. Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, Mita H, Imai K, Tokino T, Kudo R. Epigenetic inactivation of TMS1/ASC in ovarian cancer. CLIN CANCER RES. 2004; 10:2000-2006.
14. Masumoto J, Taniguchi S, Nakayama J, Shiohara M, Hidaka E, Katsuyama T, Murase S, Sagara J. Expression of apoptosis-associated speck-like protein containing a caspase recruitment domain, a pyrin N-terminal homology domain-containing protein, in normal human tissues. J HISTOCHEM CYTOCHEM. 2001; 49:1269-1275.
15. Stimson KM, Vertino PM. Methylation-mediated silencing of TMS1/ASC is accompanied by histone hypoacetylation and CpG island-localized changes in chromatin architecture. J BIOL CHEM. 2002; 277:4951-4958.
16. Yokoyama T, Sagara J, Guan X, Masumoto J, Takeoka M, Komiyama Y, Miyata K, Higuchi K, Taniguchi S. Methylation of ASC/TMS1, a proapoptotic gene responsible for activating procaspase-1, in human colorectal cancer. CANCER LETT. 2003; 202:101-108.
17. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H. p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. GASTROENTEROLOGY. 1999; 116:394-400.
18. Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, Jankowski W, Rosenberg S, Zhang J, Alnemri ES. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. CELL DEATH DIFFER. 2007; 14:1590-1604.
19. Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A, Warren SE, Wewers MD, Aderem A. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. NAT IMMUNOL. 2010; 11:1136-1142.
20. Hasegawa M, Kawase K, Inohara N, Imamura R, Yeh WC, Kinoshita T, Suda T. Mechanism of ASC-mediated apoptosis: bid-dependent apoptosis in type II cells. ONCOGENE. 2007; 26:1748-1756.
21. Parsons MJ, Patel P, Brat DJ, Colbert L, Vertino PM. Silencing of TMS1/ASC promotes resistance to anoikis in breast epithelial cells. CANCER RES. 2009; 69:1706-1711.
22. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. CANCER BIOL THER. 2005; 4:139-163.
23. Parsons MJ, Vertino PM. Dual role of TMS1/ASC in death receptor signaling. ONCOGENE. 2006; 25:6948-6958.
24. Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J, Yazdi AS. Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. PROC NATL ACAD SCI U S A. 2012; 109:18384-18389.
25. Levine AJ. The p53 tumor suppressor gene and gene product. PRINCESS TAKAMATSU SYMP. 1989; 20:221-230.
26. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. CELL. 1995; 80:293-299.
27. Malkin D, Sexsmith E, Yeger H, Williams BR, Coppes MJ. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. CANCER RES. 1994; 54:2077-2079.
28. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. CANCER RES. 1992; 52:4799-4804.
29. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. CANCER RES. 1994; 54:2095-2097.
30. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. LEUKEMIA. 2001; 15:515-522.
31. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. CELL. 1993; 74:609-619.
32. Ohtsuka T, Ryu H, Minamishima YA, Macip S, Sagara J, Nakayama KI, Aaronson SA, Lee SW. ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. NAT CELL BIOL. 2004; 6:121-128.
33. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. CELL. 1993; 75:817-825.
34. He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, Khokhar AR, Kuang J. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. ONCOGENE. 2005; 24:2929-2943.
35. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF, Sherr CJ. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. GENES DEV. 1993; 7:1559-1571.
36. Musgrove EA, Lee CS, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. PROC NATL ACAD SCI U S A. 1994; 91:8022-8026.
37. Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. MOL CELL BIOL. 2003; 23:4713-4727.
38. Machida EO, Brock MV, Hooker CM, Nakayama J, Ishida A, Amano J, Picchi MA, Belinsky SA, Herman JG, Taniguchi S, Baylin SB. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. CANCER RES. 2006; 66:6210-6218.
39. Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J NATL CANCER INST. 2004; 96:1208-1219.
40. Gopisetty G, Ramachandran K, Singal R. DNA methylation and apoptosis. MOL IMMUNOL. 2006; 43:1729-1740.
41. Ramachandran K, Gopisetty G, Gordian E, Navarro L, Hader C, Reis IM, Schulz WA, Singal R. Methylationmediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. CANCER RES. 2009; 69:1527-1535.
42. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. SCIENCE. 1991; 253:49-53.
43. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. NATURE. 2012; 481:287-294.
44. Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, Califano JA, Sidransky D. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. CANCER RES. 2004; 64:5511-5517.
45. Ying J, Srivastava G, Hsieh WS, Gao Z, Murray P, Liao SK, Ambinder R, Tao Q. The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. CLIN CANCER RES. 2005; 11:6442-6449.
46. Du W, Wang S, Zhou Q, Li X, Chu J, Chang Z, Tao Q, Ng EK, Fang J, Sung JJ, Yu J. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. ONCOGENE. 2013; 32:3319-3328.